mCRPC in focus
Transcript: Advances in mCRPC therapy
Dr Silke Gillessen
Interview recorded September 2024. All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
Yeah, I mean many, many new drugs coming. I think the androgen-receptor degraders are very promising, because I think most of us realise that there is still, you know, the androgen-receptor in a lot of patients is, is still a very important pathway.
And then I'm quite also like, let's say, excited about all the research that's going on in the, as we call it, aggressive variant prostate cancer patients. But, you know, it's very a difficult kind of population because it's, it's difficult to treat, it's quite aggressive. But, you know, finally I think we, we see some with the three with maybe some, some light on the horizon, and I guess that's really an unmet medical need. And I'm quite happy that, you know, we hopefully have some new options there quite, quite soon.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.